Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jul 2, 2001
SAN DIEGO, Jul 2, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the underwriting group managed by Thomas Weisel Partners LLC, Dain Rauscher Wessels, ABN AMRO Rothschild LLC and Lazard Freres & Co. LLC., have exercised their over-allotment option in connection with Arena's June 21, 2001 secondary offeri...
Jun 22, 2001
SAN DIEGO, June 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that its follow-on offering of 5,000,000 shares of its common stock was priced on June 21, 2001 at $27.50 per share. Of the 5,000,000 shares, Arena offered 4,000,000 shares and two selling stockholders offered a total 1,000,000 shares. Arena...
Jun 5, 2001
SAN DIEGO, June 5 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed follow-on offering of 5,000,000 shares of its common stock. Of the 5,000,000 offered shares, Arena will offer 4,000,000 shares and two sellin...
May 8, 2001
NEW YORK--(BUSINESS WIRE)--May 8, 2001--The Wall Street Transcript has published an in-depth interview with Jack Lief, CEO of Arena Pharmaceuticals (Nasdaq:ARNA), in which he talks at length about the company's future. Click here to listen to a live webcast for the RBC Dain Rauscher Wessels Biotechnology "Gene To Drugs"...
Apr 25, 2001
SAN DIEGO--(BW HealthWire)--April 25, 2001-- The Collaborative Research Program Will Begin Immediately, and Arena's Purchase of $2 Million of Axiom Preferred Stock Expected to be Completed by the End of May 2001 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") and Axiom Biotechnologies Inc. ("Ax...
Apr 17, 2001
SAN DIEGO, April 17 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported results for the quarter ended March 31, 2001. During the first quarter 2001, the Company's revenues increased by $1.3 million over the previous quarter to record revenues of $5.4 million versus no revenues for the first quarter of 2000. Reve...
Apr 3, 2001
SAN DIEGO, April 3 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will host both a telephone and internet first quarter conference call on Tuesday, April 17, 2001 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Mooney, ...
Mar 26, 2001
SAN DIEGO, March 26 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has entered into a receptor-discovery research collaboration with Taisho Pharmaceutical Co., Ltd. Phase I of the collaboration is directed toward identification studies for a receptor of interest to Taisho. Although the endogenous l...
Feb 20, 2001
SAN DIEGO, Feb. 20 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") today announced the completion of the acquisition of the outstanding capital stock of Bunsen Rush Laboratories, Inc. via merger with Arena's wholly-owned subsidiary, BRL Screening, Inc. BRL Screening is a Delaware corporation headquartered in San D...
Jan 31, 2001
SAN DIEGO, Jan. 31 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") today announced the signing of an expansion amendment to its May 29, 2000 research agreement with Taisho Pharmaceutical Co., Ltd. ("Taisho") by which Taisho has received world-wide rights to Arena's 18F Program. In addition to potential future mile...
Jan 18, 2001
SAN DIEGO, Jan. 18 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported results for the quarter ended December 31, 2000. During the fourth quarter 2000, the Company reported revenues of $4.1 million versus no revenues for the fourth quarter of 1999. Revenues in the fourth quarter of 2000 were attributable to colla...
Jan 15, 2001
SAN DIEGO, Jan. 15 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its April 14, 2000 research collaboration and license agreement with Eli Lilly and Company (NYSE: LLY), Arena has received $1.5 million in milestone payments from Lilly in the fourth quarter of 2000. These milestone pa...
Jan 4, 2001
SAN DIEGO, Jan. 4 /PRNewswire/ Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will host both a telephone and internet fourth quarter conference call on Thursday, January 18, 2001 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Mooney, ...
Dec 27, 2000
SAN DIEGO and DALLAS, Dec. 27 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") and Bunsen Rush Laboratories, Inc. ("Bunsen Rush"), a privately-held corporation, today jointly announced the signing of a Binding Letter of Intent & Memorandum of Agreement ("Agreement") for Arena to acquire all of the outstanding ca...
Nov 29, 2000
SAN DIEGO, Nov. 29 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the issuance of a Notice of Allowance ("Allowance") from the United States Patent and Trademark Office directed to a method of identifying inverse agonists to a CART-activated human serotonin receptor. An Allowance indicates that all of the r...
= add release to Briefcase